<DOC>
	<DOCNO>NCT00268853</DOCNO>
	<brief_summary>The purpose study compare standard CHOP-R regimen Cyclophosphamide , Doxorubicin , Vincristine , Prednisone , Rituximab CPOP-R ( regimen , substitute Doxorubicin Pixantrone ) . The objective show CPOP-R inferior CHOP-R .</brief_summary>
	<brief_title>A Trial Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin</brief_title>
	<detailed_description>In preclinical study , pixantrone show significantly less cardiotoxicity anthracyclines anthracenediones . In addition , patient relapse disease , receive prior maximum dos anthracyclines , tolerate high dos pixantrone minimal added cardiotoxicity . Pixantrone currently study Phase III study 3rd line aggressive NHL .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pixantrone</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Previously untreated histologically confirm diffuse large Bcell lymphoma accord REAL/WHO classification . 2 . Stage II , III IV disease 3 . CD20+ 4 . Age ≥ 18 year 5 . ECOG performance status ≤ 2 6 . At least one objectively bidimensionally measurable lesion demonstrate CT , spiral CT , MRI follow response target lesion . Patients follow site disease NOT eligible : Patients skin lesion palpable lymph node . Patients spleen bone marrow site disease . 7 . Life expectancy ≥ 3 month 8 . Serum bilirubin ≤ 1.5 x institution 's upper limit normal ( ULN ) creatinine ≤ 2.0 ULN AST ALT ≤ 2.0 x institution 's ULN . If hepatic involvement lymphoma present , AST ALT may ≤ 5.0 x institution 's ULN . 9 . LVEF ≥ 50 % determine MUGA scan . 10 . Ability comply visit schedule assessment require protocol . 11 . Signed approve informed consent , understand study procedure . 1 . Any prior chemotherapy ( except intrathecal chemotherapy diagnosis pretreatment corticosteroid therapy ) radiotherapy : Patients may receive corticosteroid pretreatment therapy 7 day randomization , pending Investigator 's decision reduce tumor burden . 2 . Histological diagnosis Tcell lymphoma Bcell lymphoma diffuse large Bcell . 3 . History indolent lymphoma 4 . Active CNS involvement base clinical evaluation . 5 . HIVrelated lymphoma . 6 . Major thoracic and/or abdominal surgery within 4 week randomization patient fully recover except diagnosis NHL . Patients minor surgery may enrol ≥ 1 week recovery period except diagnosis NHL . 7 . Clinically significant cardiovascular abnormality 8 . Serious ( NCI CTCAE grade 34 ) intercurrent infection randomization deep seat systemic mycotic infection . 9 . Clinical symptom suggest unresolved HIV , HBV HCV infection . Patients seropositivity presume due prior vaccination Hepatitis B virus resolve infection exclude . 10 . Active history another malignancy except cure basal cell carcinoma skin carcinoma situ uterine cervix . Patients remission another previous malignancy &gt; 5 year consider eligible . 11 . Known hypersensitivity excipients study drug patient receive . 12 . Any contraindication study drug describe Summary Product Characteristics package insert . 13 . Neurological contraindication vincristine ( e.g . peripheral neuropathy ) . 14 . Any condition , judgment Investigator , would place subject undue risk , interfere result study , make subject otherwise unsuitable . 15 . General status , opinion Investigator permit administration eight course CHOPR/CPOPR . 16 . Treatment investigational study drug within 30 day randomization . Patient must recover side effect investigational therapy . 17 . Potentially fertile men woman sexual partner willing use adequate contraception define Investigator study 6 month last day study drug administration . 18 . Any circumstance time study entry would preclude completion study require followup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>lymphoma</keyword>
	<keyword>NHL</keyword>
	<keyword>large cell</keyword>
	<keyword>phase II</keyword>
	<keyword>CHOP R</keyword>
	<keyword>CPOP R</keyword>
	<keyword>non Hodgkins</keyword>
</DOC>